WallStreetZenWallStreetZen

NYSE: ANRO
Alto Neuroscience Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ANRO

Based on 6 analysts offering 12 month price targets for Alto Neuroscience Inc

Min Forecast
$26.00-14.05%
Avg Forecast
$38.00+25.62%
Max Forecast
$55.00+81.82%

Should I buy or sell ANRO stock?

Based on 6 analysts offering ratings for Alto Neuroscience Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
2 analysts 33.33%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ANRO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ANRO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ANRO stock forecasts and price targets.

ANRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-17
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-05-18
lockedlocked$00.00+00.00%2026-04-22
Jones Trading
Top 20%
81
Strong BuyMaintains$44.00+45.45%2026-04-02

1 of 1

Forecast return on equity

Is ANRO forecast to generate an efficient return?

Company
-50.94%
Industry
18.55%
Market
169.71%
ANRO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ANRO forecast to generate an efficient return on assets?

Company
-43.96%
Industry
23.41%
ANRO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ANRO earnings per share forecast

What is ANRO's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$2.88
Avg 2 year Forecast
-$3.13
Avg 3 year Forecast
-$3.11

ANRO revenue forecast

What is ANRO's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$3.8M

ANRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ANRO$30.25$38.00+25.62%Strong Buy
IMTX$8.60$21.50+150.00%Strong Buy
MGTX$12.76$24.33+90.70%Strong Buy
REPL$13.03$14.75+13.20%Buy
SPTX$22.96$37.33+62.60%Strong Buy
View Top Biotech Stocks

Alto Neuroscience Stock Forecast FAQ

Is Alto Neuroscience Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NYSE: ANRO) stock is to Strong Buy ANRO stock.

Out of 6 analysts, 3 (50%) are recommending ANRO as a Strong Buy, 2 (33.33%) are recommending ANRO as a Buy, 1 (16.67%) are recommending ANRO as a Hold, 0 (0%) are recommending ANRO as a Sell, and 0 (0%) are recommending ANRO as a Strong Sell.

If you're new to stock investing, here's how to buy Alto Neuroscience stock.

What is ANRO's earnings growth forecast for 2026-2028?

(NYSE: ANRO) Alto Neuroscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.35%.

Alto Neuroscience's earnings in 2026 is -$84,238,000.On average, 13 Wall Street analysts forecast ANRO's earnings for 2026 to be -$113,095,744, with the lowest ANRO earnings forecast at -$143,061,014, and the highest ANRO earnings forecast at -$98,066,018. On average, 13 Wall Street analysts forecast ANRO's earnings for 2027 to be -$122,847,407, with the lowest ANRO earnings forecast at -$157,674,774, and the highest ANRO earnings forecast at -$78,287,997.

In 2028, ANRO is forecast to generate -$122,215,609 in earnings, with the lowest earnings forecast at -$168,827,380 and the highest earnings forecast at -$90,237,218.

What is ANRO's revenue growth forecast for 2026-2028?

(NYSE: ANRO) Alto Neuroscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.52%.

Alto Neuroscience's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast ANRO's revenue for 2026 to be $0, with the lowest ANRO revenue forecast at $0, and the highest ANRO revenue forecast at $0. On average, 11 Wall Street analysts forecast ANRO's revenue for 2027 to be $0, with the lowest ANRO revenue forecast at $0, and the highest ANRO revenue forecast at $0.

In 2028, ANRO is forecast to generate $148,884,543 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $766,398,291.

What is ANRO's forecast return on assets (ROA) for 2026-2029?

(NYSE: ANRO) forecast ROA is -43.96%, which is lower than the forecast US Biotechnology industry average of 23.41%.

What is ANRO's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ANRO price target, the average ANRO price target is $38.00, with the highest ANRO stock price forecast at $55.00 and the lowest ANRO stock price forecast at $26.00.

On average, Wall Street analysts predict that Alto Neuroscience's share price could reach $38.00 by Aug 17, 2027. The average Alto Neuroscience stock price prediction forecasts a potential upside of 25.62% from the current ANRO share price of $30.25.

What is ANRO's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: ANRO) Alto Neuroscience's current Earnings Per Share (EPS) is -$2.42. On average, analysts forecast that ANRO's EPS will be -$2.88 for 2026, with the lowest EPS forecast at -$3.65, and the highest EPS forecast at -$2.50. On average, analysts forecast that ANRO's EPS will be -$3.13 for 2027, with the lowest EPS forecast at -$4.02, and the highest EPS forecast at -$2.00. In 2028, ANRO's EPS is forecast to hit -$3.11 (min: -$4.30, max: -$2.30).

What is ANRO's forecast return on equity (ROE) for 2026-2029?

(NYSE: ANRO) forecast ROE is -50.94%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.